alatrofloxacin
(DYNZICQDCVYXFW-GIPYJWDTSA-N)
Structure
- SMILES
- CS(=O)(=O)O.NC1[C@@H]2[C@H]1CN(C2)c1nc2c(cc1F)c(=O)c(cn2c1ccc(cc1F)F)C(=O)O
- Molecular Formula:
- C21H19F3N4O6S
- Molecular Weight:
- 512.459
- Log P:
- 3.2446
- Hydrogen Bond Acceptor:
- 10
- Hydrogen Bond Donor:
- 3
- TPSA:
- 164.2
- CAS Number(s):
- 147059-75-4
Synonym(s)
1.
alatrofloxacin
2.
CP 116,517
3.
CP 116517
4.
CP-116,517
5.
CP-116517
6.
Trovan
7.
alatrofloxacin mesylate
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Asthenia | FAERS: 2 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 2 | Asthma | FAERS: 2 | US FAERS | |
| 3 | Bronchiolitis | FAERS: 2 | US FAERS | |
| 4 | Chromaturia | FAERS: 2 | US FAERS | |
| 5 | Fatigue | FAERS: 2 | US FAERS | |
| 6 | Feeling abnormal | FAERS: 2 | US FAERS | |
| 7 | Impaired work ability | FAERS: 2 | US FAERS | |
| 8 | Lymphoid tissue hyperplasia | FAERS: 2 | US FAERS | |
| 9 | Pneumonia | FAERS: 2 Canada Vigilance: 2 | Canada Vigilance US FAERS | |
| 10 | Sinusitis | FAERS: 2 | US FAERS | |
| 11 | Abdominal Pain | FAERS: 1 | US FAERS | |
| 12 | Arthralgia | FAERS: 1 | US FAERS | |
| 13 | Blood sodium decreased | FAERS: 1 | US FAERS | |
| 14 | Blood sodium increased | FAERS: 1 | US FAERS | |
| 15 | Dysuria | FAERS: 1 | US FAERS | |
| 16 | Epstein-Barr virus antigen positive | FAERS: 1 | US FAERS | |
| 17 | Hepatitis | FAERS: 1 Canada Vigilance: 1 | Canada Vigilance US FAERS | |
| 18 | Hepatotoxicity | FAERS: 1 | US FAERS | |
| 19 | Ketonuria | FAERS: 1 | US FAERS | |
| 20 | Malaise | FAERS: 1 | US FAERS | |
| 21 | Night sweats | FAERS: 1 | US FAERS | |
| 22 | Rash erythematous | FAERS: 1 | US FAERS | |
| 23 | Very low density lipoprotein decreased | FAERS: 1 | US FAERS | |
| 24 | Alopecia | Canada Vigilance: 1 | Canada Vigilance | |
| 25 | Bronchitis | Canada Vigilance: 1 | Canada Vigilance | |
| 26 | Depressed Level of Consciousness | Canada Vigilance: 1 | Canada Vigilance | |
| 27 | Dizziness | Canada Vigilance: 1 | Canada Vigilance | |
| 28 | Drug ineffective | Canada Vigilance: 3 | Canada Vigilance | |
| 29 | Epistaxis | Canada Vigilance: 1 | Canada Vigilance | |
| 30 | Erythema Multiforme | Canada Vigilance: 2 | Canada Vigilance | |
| 31 | Laryngospasm | Canada Vigilance: 1 | Canada Vigilance | |
| 32 | Leukocytosis | Canada Vigilance: 1 | Canada Vigilance | |
| 33 | Nausea | Canada Vigilance: 1 | Canada Vigilance | |
| 34 | Pharyngeal swelling | Canada Vigilance: 1 | Canada Vigilance | |
| 35 | Pulmonary congestion | Canada Vigilance: 1 | Canada Vigilance | |
| 36 | Respiratory Failure | Canada Vigilance: 4 | Canada Vigilance | |
| 37 | Tinnitus | Canada Vigilance: 1 | Canada Vigilance | |
| 38 | Tremor | Canada Vigilance: 1 | Canada Vigilance | |
| 39 | Urticaria | Canada Vigilance: 1 | Canada Vigilance |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.